ACCESS Newswire

GeneTex, Inc.

Share
GeneTex Launches PD-L1 Antibody Comprehensively Validated by MS Validated Antibodies GmbH for Immunohistochemistry

IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
PD-L1 Antibody [HL1041] IHC



The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.

Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."

The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."

GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.

Media Contact:

Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com

Contact Information

Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900

SOURCE: GeneTex, Inc.

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Global Sports Brand U.S. Polo Assn. Launches in Brazil With Grupo Pasquini2.7.2025 13:15:00 CEST | Press release

WEST PALM BEACH, FL AND SAO PAULO, BRAZIL / ACCESS Newswire / July 2, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its launch in the Brazilian market in partnership with Grupo Pasquini, a leading player in the country's fashion industry. This expansion reinforces the global, sport-inspired brand's presence in Latin America and further supports U.S. Polo Assn.'s strategic growth plan to reach new consumers around the world.U.S. Polo Assn. As U.S. Polo Assn. continues to expand its multi-billion-dollar global presence, Brazil marks an exciting new chapter in the brand's international journey. With its vibrant retail landscape and deep-rooted passion for lifestyle fashion, Brazil offers a natural fit for U.S. Polo Assn.'s authentic connection to the sport of polo. The debut collection in Brazil will showcase timeless, versatile styles across both menswear and womenswear, designed to honor the heritage of the sport while embr

Picktan Capital to Post Record Q2 Amid Market Buzz Over Possible IPO1.7.2025 20:55:00 CEST | Press release

LONDON, UK / ACCESS Newswire / July 1, 2025 / Picktan Capital, a London-headquartered wealth management firm managing over $7 billion in client assets globally, is attracting attention amid growing speculation about a potential public listing. The firm is on track to report its strongest quarterly performance to date, marking a significant milestone in its global growth strategy. With a strong emphasis on emerging technologies and disciplined capital deployment, Picktan Capital's momentum in 2024 has captured the interest of both investors and analysts. Picktan's second-quarter performance reflects a maturing investment approach grounded in both innovation and long-term value. The firm's activity across pivotal sectors, notably aerospace innovation, AI development, and satellite communications, has translated into meaningful gains and reinforced confidence in its forward strategy. Rather than chasing trends, Picktan has concentrated on sectors undergoing structural transformation. Its

DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement1.7.2025 10:00:00 CEST | Press release

AGFA HealthCare is proud to announce a landmark achievement: the adoption of its Enterprise Imaging Platform by the largest integrated health network in Latin America - and the fifth largest globally. MORTSEL, BE / ACCESS Newswire / July 1, 2025 / DASA (Diagnósticos da América S.A.) operates an extensive hospital network across Brazil and Argentina, bringing together more than 40 healthcare provider brands. In 2024, DASA and Amil announced the creation of a joint venture that consolidates 25 hospitals and over 4,400 beds, making DASA the second largest hospital group in Brazil. With 321 branches across Brazil, DASA delivers more than 15.2 million clinical studies per year, serves 55,000 patients daily, and processes around 10 million tests monthly - solidifying its leading role in healthcare delivery across the region.AGFA HealthCare After a thorough evaluation process, DASA selected AGFA HealthCare's Enterprise Imaging Platform. Key moments in the decision journey included live demons

Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202530.6.2025 23:40:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / June 30, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2025 of $37,507,184 Total cash as at April 30, 2025 of $2,475,945 Working capital deficiency as at April 30, 2025 of $527,130 Shareholder's equity as at April 30, 2025 of $33,668,042 During the quarter, the Company incurred $584,284 in cost for exploration activities at the Thunder Bay North project. The team performed drilling and follow-up geophysics activities at the Current Deposit, that were focused on expanding the high-grade ballrooms in the Lower Current and Bridge zones. The results of this program were critical in aiding the Company towards developing a revised high-grade

Karbon-X Acquires ALLCOT, Expanding Global Climate Solutions Platform30.6.2025 15:00:00 CEST | Press release

The acquisition unites climate policy expertise and emissions strategy with digital infrastructure and delivery at scale - accelerating trusted, measurable climate action worldwide. CALGARY, AB / ACCESS Newswire / June 30, 2025 / Karbon-X (OTCQX:KARX), an end-to-end climate solutions company, today announced the acquisition of ALLCOT, a global advisory firm with a legacy of supporting climate policy, carbon markets, and high-integrity project development. This acquisition brings together two complementary forces under one shared mission: to scale science-backed, verifiable climate solutions across industries and regions. Karbon-X's leadership in emissions tracking, verified portfolios, and climate strategy combined with Allcot's legacy of policy guidance, project credibility, and regional expertise form a unified climate solutions provider with end-to-end capabilities across both voluntary and compliance markets. "This is about unlocking scale with integrity," said Chad Clovis, CEO of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye